Kwality Pharmaceuticals L
NSE: KPL · Pharmaceuticals · sector
₹3,461.70NSE close 2026-10-26
Key numbers
Market cap₹3,592 cr
Price₹3,461.70
52w high / low₹3,949 / ₹1,561
P/E44.3xSector median 27.9x
P/B10.8xSector median 2.9x
Book value₹319.6
Dividend yield–Sector median 0.48%
ROE27.2%Sector median 11.7%
ROCE25.4%Sector median 12.3%
OPM24.2%Sector median 14.0%
Debt / equity0.39xSector median 0.16x
EV/EBITDA27.7xSector median 18.6x
Interest cover10.8x
Current ratio1.80x
Sales growth 3y+26.1%Sector median +9.6%
Profit growth 3y+51.2%Sector median +13.3%
PEG0.85x
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹4 cr vs borrowings ₹130 cr (FY26): borrowings are higher by ₹127 cr.
- Operating profit covered interest 10.8x in the last 12 months.
- Other income was 4% of net profit in the last 12 months.
- No dividend in the last 5 financial years.
- Price ₹3,461.70 on 2026-10-26: -12.3% from the 52-week high, +121.8% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹3,642.10 · low ₹623.75
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|
| Revenue | 116 | 111 | 111 | 123 | 157 | 162 |
| EBITDA | 26 | 24 | 25 | 29 | 39 | 41 |
| OPM % | 22.4% | 21.7% | 22.8% | 23.6% | 24.7% | 25.3% |
| Other income | 1 | 0 | 1 | 1 | 1 | 1 |
| Net profit | 14 | 12 | 14 | 16 | 25 | 26 |
| EPS (₹) | 13.95 | 11.49 | 13.60 | 15.42 | 24.39 | 24.69 |
| Revenue YoY | +35.8% | +45.6% | ||||
| Profit YoY | +74.6% | +114.8% |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 456 | 251 | 307 | 370 | 503 | 554 |
| EBITDA | 172 | 44 | 60 | 80 | 117 | 134 |
| Net profit | 120 | 19 | 24 | 40 | 67 | 81 |
| EPS (₹) | 115.70 | 18.45 | 23.11 | 38.36 | 64.90 | 78.10 |
| Revenue growth | -45.0% | +22.4% | +20.5% | +35.9% | – | |
| Profit growth | -83.8% | +23.2% | +66.2% | +69.0% | – | |
| Dividend / share (₹) | – | – | – | – | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +26.1% | – | – |
| Net profit | +51.2% | – | – |
| EPS | +52.1% | – | – |
| Share price | – | – (2y) | – |
Balance sheet
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Shareholders' equity | 264 | 332 |
| Borrowings | 112 | 130 |
| Cash & equivalents | 15 | 4 |
| Total assets | 447 | 592 |
| Fixed assets | 144 | 150 |
| Capital work in progress | 0 | 17 |
| Investments | 0 | 0 |
| Receivables | 154 | 280 |
| Inventory | 83 | 78 |
| Payables | 56 | 102 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Cash from operations | 53 | 17 |
| Cash from investing | -29 | -35 |
| Cash from financing | -14 | 7 |
| Capex | 25 | 49 |
| Free cash flow | 28 | -32 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY25 | FY26 |
|---|---|---|
| ROE % | 15.1% | 20.3% |
| ROCE % | 17.0% | 21.7% |
| Debtor days | 152 | 203 |
| Inventory days | 167 | 111 |
| Payable days | 112 | 144 |
| Cash conversion cycle (days) | 207 | 170 |
| Working capital days | 113 | 131 |
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| KPL | ₹3,592 cr | 44.3x | 10.8x | 27.2% | 25.4% | 24.2% | +26.1% | – |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2017-01-05 | Dividend | Interim Dividend Rs 0.6 |
Documents
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | KPL |
| BSE code | 539997 |
| ISIN | INE552U01010 |
| Face value | ₹10.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-22 from BSE company filings (inline XBRL: Integrated Filing - Finance) + BSE results summary for earlier years; price = NSE close 2026-10-26.